Positive Late-Breaking Data for Incyte’s First-in-Class mutCALR-targeted therapy INCA033989 in Essential Thrombocythemia Presented at EHA2025

Positive Late-Breaking Data for Incyte’s First-in-Class mutCALR-targeted therapy INCA033989 in Essential Thrombocythemia Presented at EHA2025

WILMINGTON, Del.--(BUSINESS WIRE)--Jun 15, 2025-

Promising Results for Novel Therapy in CALR-Mutant Myeloproliferative Neoplasms

WILMINGTON, DE — First clinical data for INCA033989, a novel monoclonal antibody from Incyte (Nasdaq: INCY) targeting CALR-mutant myeloproliferative neoplasms (MPNs), were presented at the European Hematology Association (EHA) Congress 2025. The findings highlight both the safety and the potential disease-modifying capabilities of the agent in treating high-risk essential thrombocythemia (ET). The Phase 1/2 studies focused on patients with CALR-…

Clinical Trial Breakthrough: Incyte's New Essential Thrombocythemia Drug Achieves 86% Response Rate in High-Risk Patients

Novel mutCALR-targeted therapy shows unprecedented 89% reduction in disease markers for essential thrombocythemia. See complete efficacy and safety data.